Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04160377
Other study ID # 19-08-01-XY-0001
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 1, 2019
Est. completion date September 30, 2022

Study information

Verified date April 2022
Source Central South University
Contact Xueqin Li
Phone 0086-15015102836
Email 876659651@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims at investigating the special effectiveness of antidepressant effect of Fluvoxamine for endogenous depression. The investigators also aim to assess the effect of Fluvoxamine on the multimodal magnetic resonance imaging(MRI), blood cytokines, feces bacteria flora and neuropsychological performance in depression patients with melancholic features. The investigators further aim to identify the predictors of Fluvoxamine's antidepressant effeect using the above techniques.


Description:

This study aims at investigating the special effectiveness of antidepressant effect of Fluvoxamine for melancholia. The investigators also aim to assess the effect of Fluvoxamine on the multimodal magnetic resonance imaging(MRI), blood cytokines, feces bacteria flora and neuropsychological performance in depression patients with melancholic features. The investigators further aim to identify the predictors of Fluvoxamine's antidepressant effeect using the above techniques.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date September 30, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Adult (18-55 years, both sexes), with DSM-4 criteria for MDD without psychosis, as determined by a structured clinical interview Mini International Neuropsychiatric Interview - Moderate to severe depression, as defined by a pretreatment score =17 on the HDRS-17 scale - Informed consent to participate in this study - ethinic Han, right-handed, Junior high school education or above Exclusion Criteria: - A history of bipolar disorder, schizophrenia, schizoaffective disorder, obsessive-compulsive disorder, panic disorder, or documented Axis II diagnoses; active suicidal intention, as determined by clinical interview - Active or recent (<12 months) substance abuse or dependence; excluding nicotine - Presence of ECT treatment in recent 6 months - period of pregnancy or lactation - hearing disorder or colour blindness - Immediate relatives have bipolar disorder or mania disorder

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fluvoxamine
Fluvoxamine was assigned to be the treatment for the depression patients with melancholic features or not .

Locations

Country Name City State
China Mental Health Institute & Faculty of Psychiatry of The Second Xiangya Hospital, Central South University Changsha Hunan

Sponsors (1)

Lead Sponsor Collaborator
Lingjiang Li

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Halstead-Reitan neuropsychological test battery for adults(HRB) Halstead-Reitan neuropsychological test battery for adults assesses the basic functions of the brain,including perception, orientation, attention, action speed and memory. Baseline, 1 months, 2 months
Other Wechsler Scale (Digital Span) Wechsler Scale (Digital Span) assesses the Attention and short-term memory of the subjects. Baseline, 1 months, 2 months
Other Electroencephalogram (EEG) EEG Microstate Parameters data like"ECG QT Interval" or "EEG power in the alpha band, etc., were collected at a 5000 Hz sampling rate, using a 64-channel Ag-Cl electrode (Brain Products) for both resting-state and task-state. Baseline, 2 weeks
Primary Change in Hamilton Depression Rating Scale-17 item (HAMD-17) Interview-based questionnaire used to measure the severity of depression. Consists of 17 items with a score calculated. Higher scores are associated with more severe depression. Baseline, 2weeks, 1 months, 2 months
Primary Change in Hamilton Anxiety Rating Scale-14 item (HAMA-14) Interview-based questionnaire used to measure the severity of anxiety. Consists of 14 items with a score calculated. Higher scores are associated with more severe anxiety. Baseline, 1 months, 2 months
Primary Change in voxel-based morphometry of grey matter, white matter as assessed by structural magnetic resonancce imaging Participants will receive resting-state functional magnetic resonance imaging (MRI). Scans will be performed on a 3.0- T Siemens Magnetom Skyra scanner (Siemens Healthineers, Erlangen, Germany). During scanning, all participants were instructed to remain motionless, and to think of nothing in particular but to not fall asleep. Baseline, 2 months
Primary Change in Functional connectivity Change in Functional connectivity of the brain networks as assessed by measure of connectivity in multimodal MRI. Baseline, 2 months
Secondary Change in peripheral blood cytokines Peripheral blood sample will be collected and the concentration of IL-6, TNF-a, and CRP will be assessed. Baseline, 1 months, 2 months
Secondary Change in feces bacterial flora The objective of investigator is to characterize gut microbiome in patients with TRD. To explore the specific diversity of gut microbiome. The stool samples were collected in the collection kits at the baseline, and were frozen at -80 °C. After the process of DNA Purification, 16S rRNA Gene Amplification and Illumina MiSeq sequencing, the study finally find the abundance and diversity of microbiota. Baseline, 1 months, 2 months
Secondary Change in Congruent STROOP Time to Complete (Executive Function) Stroop Colour Naming Test (STROOP) is a cognitive test designed to assess the ability to inhibit a prepotent response to reading words while performing a task that requires attention control. It comprises two sheets with 50 words on each, and each word is the name of a colour. On the first sheet, the Congruent STROOP Sheet, the word and ink colour match; on the Incongruent STROOP Sheet, the word and ink colour do not match. For each sheet, the patient has 4 minutes to name the ink colour of each word. When the patient finishes the sheet, or once 4 minutes is up, the clinician notes the time taken and counts the number of correct and incorrect responses. The scale ranges from 0-100, the higher score the greater the cognitive flexibility. Baseline, 1 months, 2 months
Secondary Change in DSST (Number of Correct Symbols) Digit Symbol Substitution Test (DSST) is a cognitive test designed to assess psychomotor speed of performance requiring visual perception, spatial decision-making, and motor skills. It consists of 133 digits and requires the patient to substitute each digit with a simple symbol in a 90-second period. Each correct symbol is counted, and the total score ranges from 0 (less than normal functioning) to 133 (greater than normal functioning)." as a description of DSST. Baseline, 1 months, 2 months
Secondary Improvement on Snaith-Hamilton Pleasure Scale (SHAPS) The Snaith-Hamilton Pleasure Scale (SHAPS) assesses the anhedonia symptoms of MDD patients, with higher score indicating more severe anhedonia. Evaluating the patient's pleasure experience and choosing the degree of agreement with the happy response in some pleasant situations, and each item was rated on a 4-point scale."1 = Strongly agree, 2 = agree, 3 = disagree and 4
= strongly disagree" This scale evaluates the status of patients in the recent period of time, The total score of the scale is the sum of the scores of 14 items, with a total score of 14-56. The higher the total score, the more serious the anhedonia.
Baseline, 1 months, 2 months
Secondary Young Manic Rating Scale (YMSR) The YMSR assesses the manic symptoms of the subjects. Baseline, 1 months, 2 months
Secondary Life Event Scale (LES) The LES assesses the effects of some life events on the subjects. Baseline, 1 months, 2 months
Secondary Beck Scale for Suicide Ideation(BSI) The BSI assesses the Suicide Ideation of the subjects, including two time points, the latest week and when the subjects were the most depressive. Baseline, 1 months, 2 months
Secondary Hopkins Vocabulary Learning Test-Revised (HVLT-R) The HVLT-R assesses the memory and the cognition of the subjects. Baseline, 1 months, 2 months
Secondary Sydney Melancholia Prototype Index (SMPI) The SMPI aims to identify the melancholic and non-melancholic depression. Baseline, 1 months, 2 months
Secondary Generalized Anxiety Disoder-7 (GAD-7) The GAD-7 aims to assesses the severity of anxious symtoms. Baseline, 1 months, 2 months
Secondary Self-reported Quick Inventory of Depressive Symptomatology (QIDS-SR) Scale The QIDS-SR assesses the depressive symtoms in latest week of subjects quickly. Baseline, 1 months, 2 months
Secondary Dimensional Anhedonia Rating Scale (DARS) The DARS assesses different dimensions in Anhedonia of the subjects. Baseline, 1 months, 2 months
Secondary Child Trauma Scale (CTQ) The CTQ assesses child trauma happen to the subjects. Baseline, 1 months, 2 months
Secondary Sheehan Disability Scale (SDS) The SDS assesses the impairment in the occupational, familial and social ability of the subjects. Baseline, 1 months, 2 months
Secondary Pittsburgh Sleep Quality Index (PSQI) The PSQI assesses the sleep quality of the subjects. Baseline, 1 months, 2 months
Secondary Perceived Deficit Questionnaire for Depression (PDQ-D) The PDQ-D assesses the perceived deficit of the subjects Baseline, 1 months, 2 months
Secondary Medication Adherence Rating Scale (MARS) The MARS assesses the medication adherence condition of the subjects 1 months, 2 months
Secondary Rating Scale for Side Effects (SERS) The SERS assesses the side effects of medication condition in the subjects 1 months, 2 months
See also
  Status Clinical Trial Phase
Completed NCT01316926 - Paxil CR Bioequivalence Study Brazil Phase 1
Recruiting NCT06187454 - Transcranial Direct Current Stimulation for Depression N/A
Completed NCT04469322 - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression N/A
Recruiting NCT05768126 - Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine Phase 4
Completed NCT03219879 - Telephone-administered Relapse Prevention for Depression N/A
Recruiting NCT06038721 - Unified Protocol: Community Connections N/A
Completed NCT03043560 - Study to Treat Major Depressive Disorder With a New Medication Phase 2
Completed NCT04091139 - Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong Phase 2/Phase 3
Completed NCT00069459 - Seasonal Affective Depression (SAD) Study Phase 1
Recruiting NCT05503966 - Combining Antidepressants and Attention Bias Modification in Depression N/A
Recruiting NCT03001245 - Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents N/A
Completed NCT02939560 - TMS for Adults With Autism and Depression N/A
Completed NCT02452892 - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) N/A
Completed NCT02542891 - European Comparative Effectiveness Research on Internet-based Depression Treatment N/A
Withdrawn NCT02238730 - Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy N/A
Completed NCT02306551 - Well Being And Resilience: Mechanisms of Transmission of Health and Risk
Completed NCT02224508 - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks N/A
Completed NCT01407575 - Buprenorphine for Treatment Resistant Depression Phase 3
Completed NCT01597661 - Bupropion & Cardio Birth Defect (Slone) N/A
Completed NCT01093053 - Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations N/A